Sacituzumab tirumotecan

Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. The internalization and anti-tumor activity of Sacituzumab tirumotecan are enhanced in tumor cell lines with EGFR mutations. Sacituzumab tirumotecan can be used in the research of triple negative breast cancer (TNBC), non small cell lung cancer (NSCLC) and other cancers[1][2].

Product Specifications

CAS Number

[2768350-77-0]

Product Name Alternative

SKB264; MK-2870

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; TROP2

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sacituzumab-tirumotecan.html

Purity

99.63

Smiles

[Sacituzumabtirumotecan]

Molecular Weight

157907 (average)

References & Citations

[1]Xu B, et, al. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC) : Results from the phase III OptiTROP-Breast01 study. Special Clinical Science Symposia. May 29, 2024.|[2]Fang W, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial[J]. bmj, 2025, 389.